As of January 1, 2025, Abomics Oy and Multirec Oy have merged their operations. This union brings together the expertise of two industry leaders, enabling the combined organization to offer even more comprehensive solutions for healthcare and pharmaceutical professionals.
Abomics specializes in genetics and pharmacogenetic analyses, while Multirec focuses on the development and maintenance of medical databases used to support treatment decisions.
The merger allows the strengths of both companies to shine, providing customers with enhanced integration opportunities and decision-support tools for patient care. Moving forward, pharmacogenetic data and prescription support information will be available from a single provider, streamlining healthcare operations and promoting the safe and effective use of medications.
“This merger is an important step toward a future where genetics and pharmacogenetics play an even more impactful role in medical decision-making. By combining the expertise of Abomics and Multirec, we can deliver more comprehensive solutions that advance personalized medication management,” says Sami Miettinen, CEO of Abomics.
Miettinen anticipates that 2025, the first year of the merger, will bring new growth opportunities both in Finland and internationally.
“The Ostrobothnia wellbeing services county will be the first to implement a system where Abomics’ pharmacogenetic data is integrated into patient record systems. Our hope is that this world-class integration model will quickly spread to both private and public healthcare. Additionally, we remain committed to driving international growth through tailored service concepts for various customer segments,” Miettinen adds.
This strategic merger marks the beginning of a new era for both companies, combining their strengths to support the evolving needs of healthcare professionals globally.
